{
    "clinical_study": {
        "@rank": "168001", 
        "acronym": "MAINTAIN", 
        "arm_group": [
            {
                "arm_group_label": "Etanercept", 
                "description": "Etanercept: administered as first line biotherapy in RA during the period of the study"
            }, 
            {
                "arm_group_label": "Adalimumab", 
                "description": "Adalimumab: administered as first line biotherpy in RA during the period of the study"
            }, 
            {
                "arm_group_label": "Infliximab", 
                "description": "Infliximab: administered as first line biotherpy in RA during the period of the study"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy\n      in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated\n      factors, and retention rates of possible second-line tumor necrosis factor \u03b1 inhibitors\n      (TNFi)."
        }, 
        "brief_title": "Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice", 
        "completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this retrolective, multicentric study, medical charts of RA patients starting TNFi\n      between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The\n      retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done\n      after adjustment using a Cox model. Factors associated with better retention were identified\n      by multivariate analysis. Medical charts of all patients with RA starting a first TNF\u03b1\n      inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France)\n      and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in\n      detail by 2 rheumatologist investigators"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  RA defined by the 1987 ACR criteria [18]\n\n          -  first TNF\u03b1 inhibitor prescribed in the previously mentioned period\n\n          -  TNF\u03b1 inhibitor prescribed as first-line biotherapy\n\n          -  undergone at least one evaluation in the center after treatment initiation\n\n        Exclusion Criteria:\n\n          -  previously received another biotherapy\n\n          -  TNF\u03b1 inhibitor was prescribed in an RCT\n\n          -  refused to participate"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "RA defined by the 1987 ACR criteria [18]; first TNF\u03b1 inhibitor prescribed in the\n        previously mentioned period; TNF\u03b1 inhibitor prescribed as first-line biotherapy; and\n        patients had undergone at least one evaluation in the center after treatment initiation.\n        Patients were excluded if: they had previously received another biotherapy; the TNF\u03b1\n        inhibitor was prescribed in an RCT; or they refused to participate."
            }
        }, 
        "enrollment": {
            "#text": "780", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692899", 
            "org_study_id": "NRB1800007", 
            "secondary_id": "B1801356"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "TNFR-Fc fusion protein", 
                "Infliximab", 
                "Adalimumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Retention Rates", 
            "of Adalimumab", 
            "Etanercept and Infliximab", 
            "as First and Second-Line Biotherapy", 
            "in Patients with Rheumatoid Arthritis", 
            "in Daily Practice.", 
            "TNF inhibitors", 
            "biotherapy", 
            "retrospective study"
        ], 
        "lastchanged_date": "September 24, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=NRB1800007&StudyName=Retention%20Rates%20of%20Adalimumab%2C%20Etanercept%20and%20Infliximab%20as%20First%20and%20Second-Line%20Biotherapy%20in%20Patients%20with%20Rheumatoid%20Arthritis%20in%20"
        }, 
        "number_of_groups": "3", 
        "official_title": "Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "France: The Commission nationale de l\u2019informatique et des libert\u00e9s", 
                "France: Conseil National de l'Or"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compare retention rates of TNF\u03b1 inhibitor monoclonal antibodies (adalimumab and infliximab) and the soluble receptor (etanercept)", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Causes of discontinuing these treatments", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Determine the factors associated with better retention of the first TNF\u03b1 inhibitors", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Compare retention rates of possible second-line TNF\u03b1 inhibitors", 
                "safety_issue": "Yes", 
                "time_frame": "4 years"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "collaborator": {
                "agency": "scientific steering committee of KOL in rheumatology", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2012"
    }
}